Cypress Bioscience, Inc.
    About Cypress Our Products Our Research Investor Information Newsroom Contact Home


 
Corporate Governance
Investor FAQs
Investor Relations
     Stock Information
     News
     Fundamentals
     Analyst Coverage
     Earnings Estimates
     Dividends and Splits
     SEC Filings
     Request Information
     Investor Presentation
  
 

Investor Relations

Corporate profile

Cypress Bioscience is a pharmaceutical company dedicated to the development of innovative drugs targeting large unmet medical needs for patients suffering from a variety of disorders of the central nervous system.  Since 1999, Cypress has received multiple FDA approvals, including for Prosorba™, a medical device for rheumatoid arthritis, and Savella® (milnacipran HCl), for fibromyalgia.  The Company focuses on generating stockholder value by reaching clinical development milestones as quickly and efficiently as possible. more

Stock Quote
CYPB (common stock)
Exchange NASDAQ (US Dollar)
Price $3.34
Change (%) 0.05 (1.52%)
Volume 339,126
Date as of 09/02/2010 01:48 pm ET
Minimum 20 minute delay
Refresh quote

Upcoming Events

There are currently no events scheduled.

Featured Report

There are currently no items available.

Recent News

Date Title
08/26/2010 Cypress Bioscience Acquires Novel Intranasal Carbetocin Therapy for Autism Printer Friendly Version
08/26/2010 Cypress Bioscience Licenses Alexza Pharmaceutical's Staccato(R) Nicotine Printer Friendly Version
08/17/2010 Cypress Bioscience Sends Letter to Ramius Printer Friendly Version
08/10/2010 Cypress Bioscience Receives Consent for BioLineRx In-License Agreement Printer Friendly Version

Contact Information

Primary IR Contact
Investor Relations
Cypress Bioscience, Inc.
4350 Executive Drive
Suite 325
San Diego CA, 92121
Phone: (858) 452-2323
Fax: (858) 452-1222
E-mail: ir-info@cypressbio.com
  
© 2005-2009 Cypress Bioscience, Inc.

 Privacy      Legal Disclaimer